

MEDX HOLDINGS, INC.
A WYOMING CORPORATION

COMPANY INFORMATION AND DISCLOSURE STATEMENT

Pursuant to Pink Sheet Basic Disclosure Guidelines

All information in this information and Disclosure Statement has been compiled to fulfill the disclosure requirement of the OTC Markets regarding Pink Sheet Basic Disclosure Guidelines.

No Dealer, salesman or any other person has been authorized to give any information, or to make any representations. Not contained herein in connection with the issuer. Such information or representations if made should not be relied upon as having been authorized by the issuer and;

Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written

The undersigned hereby certifies that the information herein is true and correct to the best of their knowledge and belief.

Date: February 19, 2017

MedX Holdings, Inc.

/s/ Kathleen Robertson

Position: Director and CEO

Email: kathy@medxholdings.com

Phone: 877-337-3756

MEDX HOLDINGS, INC.
DISCLOSURE STATEMENT

December 31, 2016

Item 1: The exact name of the issuer and the address of its executive offices:

The exact name of the issuer is: MedX Holdings, Inc.
August 12, 2015 – Cantor Group
November 13, 2006 – Disaboom, Inc.
September 5, 2006 – Disaboo, Inc.

Item 2: The Address of its principal executive offices:

1621 Central Avenue
Cheyenne, WY 82001

Phone: 877-225-0421
Fax: 954-337-3756
Website: www.medxholdings.com

Item 3: Security Information

Security Symbol: MEDH
CUSIP Number: 58403T 107
Common Stock: 32,644,016
Par Value: \$0.001 on both Common and Preferred Shares

As of:	12/31/2015	Par Value	12/31/2016	Par Value
Total Authorized Common	100,000,000	\$0.001	100,000,000	\$0.001
Total Authorized Preferred:				
Series A Preferred	10,000,000	\$0.001	10,000,000	\$0.001
Blank Check Preferred				
Shareholders				

Transfer Agent:

Daniel Bell, Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, Colorado 80209
Phone: 303-282-4800

CST currently meets all requirement and is registered under the Securities Exchange Act.

Restriction on transfer of Securities or suspensions by the SEC in the past 12 months:

None

Stock Splits:

None

Item 4: Issuance History:

4/20/2016 – Imperial Creations Corp: 1,200,000 shares of Common Stock, par value
\$0.001

4/20/2016 – The Uptick Group: 1,350,000 Shares of Common Stock, par value \$0.001

Item 5: Financial Statement

- Balance Statement
- Profit and Loss Statement
- Statement of Cash Flows
- Financial Notes

Item 6: Nature of the Issuer's Business

MEDH was sold during the fiscal year of 2016 to Kathleen A. Robertson. Donald Schellpfeffer MD/PHD resigned as President, Secretary and Chief Executive Officer. MedX is a developmental business. In 2016 MedX acquired MedX Pharmaceuticals which is licensed as a Mfr./Wholesaler/Repackager of Pharmaceuticals Drugs in the state of Alabama.

MedX Pharmaceuticals secured a relationship with Amneal Pharmaceuticals who is one of the largest FDA approved manufactures. Our focused product during 2016 was a 5% Topical Lidocaine Ointment which is an RX Product.

The Company's fiscal year end is December 31st. The Company has not been involved in any bankruptcy, receivership, or any similar proceeding.

The Company is not currently subject to any legal action or in default of any debt covenants.

A. The form of organization of the Issuer:

MedX Holdings, Inc. is a Wyoming Corporation

MedX Pharmaceuticals, Inc. is a Alabama Corporation and is a "Arm's Length" Wholly-owned Subsidiary of MedX Holdings, Inc.

B. This Year that the Issuer (or predecessor was organized):

The Company was incorporated on September 5, 2006 as Disaboo, Inc. under the laws of the state of Colorado.

Item 7: Describe the Issuer's Facilities

Corporate Office: MedX Holdings, Inc.

1621 Central Avenue
Cheyenne, WY 82001

Corporate Office: MedX Pharmaceuticals, Inc.

750 Lakeside Drive, Suite A, Mobile Alabama

Sales Office: MedX Pharmaceuticals, Inc.

1500 Cypress Creek Road, Fort Lauderdale, FL 33304

Item 8: Officers, Directors and Control Persons:

A. Kathleen Robertson servers of Officer, Director and Control Person.

B. Legal/Disciplinary History:

None

C. Beneficial Owner

Kathleen Robertson
1621 Central Avenue
Cheyenne, Wyoming 92001
Percentage: Greater than 76%

Item 9: Third Party Providers

Legal Counsel:

Lorin A. Rosen, Esq.
Managing Attorney
Lar Law Firm
6 Butler Court
Centereach, NY 11720

Irick CPA
Box 732
Counselor, NM 87018

Subsequent Events:

January 2017 – MedX Pharmaceutical officially went out of business due price competition and regulatory laws. Thus, MedX Pharmaceuticals was forced to vacate the office in Mobile Alabama and was released from their 5-Year lease with no penalty or liability. MedX Pharmaceuticals also vacated the sales office in Fort Lauderdale, FL with a negotiated settlement of \$3,200. This payment is still pending.

Item 10 : Issuer Certification:

I Kathleen Robertson certify that:

1. I have reviewed this Annual Report
2. Based on my knowledge, this disclosure statement does not contain any untrue statements of material fact or omit to state a material fact necessary to make the statements made. In light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the period presented in this disclosure.

/s/ Kathleen Robertson, CEO

Kathleen Robertson, CEO